Eli Lilly's CEO Says This Could Be a Game Changer for Its Business [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
It has some excellent GLP-1 drugs in its portfolio -- Zepbound and Mounjaro -- which are in high demand from patients looking to lose weight and become healthier. The knock on the stock these days, however, is that it may have gotten too expensive, and that demand may also slow down in the future. As a result, shares of Eli Lilly haven't been all that hot of late. Instead, they've been in a bit of a tailspin. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » But investors shouldn't count out the healthcare stock , as its CEO believes there could be a catalyst in the near future. Image source: Getty Images. Medicare coverage for GLP-1 could be huge for Eli Lilly Eli Lilly's business has been impressive. The company has been generating fantastic growth, and it's still in the early innings of what's proving t
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US [Yahoo! Finance]Yahoo! Finance
- Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPR Newswire
- Franklin Rising Dividends Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
- Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (LLY) had its price target lowered by Guggenheim from $1,168.00 to $1,163.00. They now have a "buy" rating on the stock.MarketBeat
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- LLY's page on the SEC website